# A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

> **NCT00481702** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 300 (—)

## Conditions studied

- Intra-abdominal Infection

## Interventions

- **DRUG:** Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks
- **DRUG:** MK0826, /Duration of Treatment : 8 Weeks
- **DRUG:** Comparator: metronidazole / Duration of Treatment: 8 Weeks

## Key facts

- **NCT ID:** NCT00481702
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 300 (—)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481702, "A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00481702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*